3rd Quarter - Report

DAIICHI SANKYO, INC. for DAIICHI SANKYO INC

Firm
Client
Income
—
Expenses
$110,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Discussions regarding the Affordable Health Care Act (ACA)

Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.

LobbyistCovered position, as disclosed
LANCE GILGORE —

Medicare/Medicaid MMM

Discussions regarding Medicare and Medicaid

Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.

LobbyistCovered position, as disclosed
LANCE GILGORE —

Pharmacy PHA

H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 Discussions regarding opioid abuse Discussions regarding 340B drug discount program

Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.

LobbyistCovered position, as disclosed
LANCE GILGORE —

Bills named: H.R. 2025 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.